for which I wrote the accompanying editorial, 5 where only eight participants in the oral immunotherapy arm were recorded as having an SAE. By contrast, 52 participants had epinephrine administered; one participant needed three doses of epinephrine on a single occasion, and two participants needed epinephrine on six separate occasions. Of the 82 episodes of epinephrine administration, only two were deemed to be SAEs.
Oral immunotherapy clearly works in the majority of participants, but the journey is not without significant hazard. It is interesting to note how many studies have failed to measure its impact on quality of life, and the data on this that have emerged are not overly promising. count, which was the best possible method for this study. Regardless of the real compliance, the polypill was shown to be effective in reducing major cardiovascular events, and the safety profile was similar between the two study groups. We agree that both study groups had well controlled blood pressure at study baseline, which is probably because of the implementation of a rigorous cardiovascular disease surveillance programme in the Iranian public health network. 4 As a result of this programme, which has been ongoing for almost a decade, all individuals in our study received freeof-charge preventive services for blood pressure control. Polypill might indeed have stronger effects in reducing cardiovascular events in populations without similar preventive services. We also agree that statin and aspirin are two important components in our polypill that contributed to reducing cardiovascular events.
We developed the PolyIran Quality Control Program (PIQCP) tool to ensure that both trial groups received similar healthy lifestyle education. The PIQCP results showed that the quality of delivering lifestyle advice to the two study arms was almost the same. 5 We agree with the comment that the limitations of our trial and other studies considering polypill strategy should be carefully taken into account before recommending polypill for the general population.
We declare no competing interests.
Perception of severity of adverse events in oral immunotherapy
Derek Chu and colleagues 1 report on the discrepancy between the efficacy of peanut oral immunotherapy and the considerably increased risk of allergic and anaphylactic reactions during treatment. A further disconnect exists between what is formally designated a serious adverse event (SAE) and what a family would consider as such in real life. The former is defined as causing death, a life-threatening state, hospitalisation, disablility, congenital abnormality, or an event that necessitates intervention to prevent permanent impairment or damage. 2 An important medical event might be considered an SAE when, based on appropriate medical judgment, it could jeopardise the participant and might necessitate medical intervention to prevent one of the outcomes listed above. 3 A family is likely to perceive their use of an epinephrine autoinjector during an oral immunotherapy trial as fulfilling the latter, regardless of whether medical judgement is made by a trial study team as to its necessity. This was aptly demonstrated in by far the largest study to date, the PALISADE trial, 4
Authors' reply
We appreciate the opportunity to respond to Michael Perkin's queries about our study. 1 In medicine, large and well done randomised trials generate more trustworthy evidence about treatments than uncontrolled observations. 2,3 For any given clinical question, well done systematic reviews and meta-analyses provide the most credible information for decision to these standards, especially since immunotherapy is a lifelong treatment but has been not shown to be a cure. It is therefore incumbent upon all parties involved-researchers, patients, providers, funders, regulators, advocates, and critics-to demand that potential new treatments for food allergy are proven in large, rigorous randomised controlled trials to the highest standards of medicine before they are accepted as definitively and universally beneficial. To achieve a world without food allergy, unbiased facts generated through systematic and united multinational collaborative efforts are required, which we are openly committed to. making by transparently evaluating and synthesising the totality of evidence of a greater number and wider range of patients than any individual study alone. 4 In the PACE study, 1 we systematically reviewed all randomised trials done globally until 2018 to compare participants receiving oral immunotherapy with those receiving no immunotherapy. The aim was to synthesise the best available evidence on efficacy and safety of the intervention. We found moderatecertainty and high-certainty evidence that, compared with control groups (placebo or no oral immunotherapy), patients given current forms of peanut oral immunotherapy could often be desensitised; however, we also found a large increase in the risk and frequency of anaphylaxis, serious adverse events, epinephrine use, and other allergic reactions, along with low-certainty evidence of no improvement in quality of life. 4 Perkin comments that the definition of a serious adverse event by the US Food and Drug Administration might underestimate what a family considers as a serious adverse event. Because we synthesised the available facts and did not issue judgements on the current forms of peanut oral immunotherapy, Perkin's thoughtful comments help to frame the concept of the risks associated with current forms of peanut oral immunotherapy and how these risks might affect perceived changes in quality of life. They also further reinforce the idea that a comprehensive assessment of the values and preferences on treatments for food allergy is needed from the full spectrum of patients and caregivers.
Patients need and deserve therapies that are proven right and are not hastily implemented, and fiduciaries, caregivers, and providers want to optimise health without a substantial risk or net harm to the patient. Trustworthy claims need to be backed up by robust data. Current forms of oral immunotherapy are no exception
